The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Nextrast (Inst); Novocure (Inst); Nucana (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme; Nucana
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Speakers' Bureau - BMS; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Gina M. Vaccaro
Consulting or Advisory Role - Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Exelixis; GlaxoSmithKline; Helsinn Therapeutics; Incyte; MSD; Pfizer; QED Therapeutics; SERVIER; Taiho Pharmaceutical
Speakers' Bureau - Incyte
Research Funding - Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; E.R. Squibb Sons, LLC; Eisai; Foundation Medicine
 
Ursa Brown-Glaberman
Consulting or Advisory Role - Biotheranostics; Macrogenics; Novartis; Sanofi/Aventis; Seagen; Taiho Oncology
Speakers' Bureau - Seagen
 
Juneko E. Grilley-Olson
Consulting or Advisory Role - Sorrento Therapeutics; SpringWorks Therapeutics
Research Funding - Genentech (Inst); Iovance Biotherapeutics (Inst); Loxo (Inst); Pfizer (Inst); Seagen (Inst)
 
Hedy L. Kindler
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Deciphera; Inhibrx; Novocure; Seagen
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Deciphera (Inst); Fibrogen (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Polaris (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); Verastem (Inst); Vivace Therapeutics (Inst)
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; BioMed Valley Discoveries; Seagen
 
Elisabeth I. Heath
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Caris Life Sciences; Genzyme; Janssen; Johnson & Johnson/Janssen; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Sanofi; Seagen
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Calithera Biosciences (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pharmacyclics (Inst); Plexxikon (Inst); POINT Biopharma (Inst); Roche (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
Other Relationship - Caris Centers of Excellence
 
Sarina A. Piha-Paul
Consulting or Advisory Role - CRC Oncology
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); F-Star Beta Limited (Inst); F-Star Therapeutics, Ltd. (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Hengrui Pharmaceutical (Inst); HiberCell (Inst); Immunomedics (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Purinomia (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Synologic Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst); ZielBio (Inst)
 
Allison Wehr
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Hailing Lu
No Relationships to Disclose
 
Jonathan Hayman
Employment - Seagen
 
David L Bajor
Consulting or Advisory Role - Avoro Capital Advisors; BridgeBio Pharma; Cardinal Health; Tempus
Speakers' Bureau - Natera
Research Funding - Abbvie; Apexigen (Inst); Bristol-Myers Squibb/Celgene (Inst); Calithera Biosciences (Inst); GlaxoSmithKline (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Tesaro (Inst)